Vanguard Group’s Palisade Bio PALI Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q4 | $4.97M | Buy |
+2,115,622
| New | +$4.07M | ﹤0.01% | 3256 |
|
|
2024
Q2 | – | Sell |
-4,537
| Closed | -$27.2K | – | 4434 |
|
|
2024
Q1 | $27.2K | Hold |
4,537
| – | – | ﹤0.01% | 4370 |
|
|
2023
Q4 | $40.2K | Hold |
4,537
| – | – | ﹤0.01% | 4385 |
|
|
2023
Q3 | $39.6K | Buy |
4,537
+2,166
| +91% | +$39.7K | ﹤0.01% | 4438 |
|
|
2023
Q2 | $60.5K | Buy |
+2,371
| New | +$59.2K | ﹤0.01% | 4440 |
|
|
2022
Q4 | – | Sell |
-103
| Closed | -$8K | – | 4548 |
|
|
2022
Q3 | $8K | Sell |
103
-259
| -72% | -$54.8K | ﹤0.01% | 4600 |
|
|
2022
Q2 | $110K | Hold |
362
| – | – | ﹤0.01% | 4537 |
|
|
2022
Q1 | $288K | Buy |
362
+37
| +11% | +$29.9K | ﹤0.01% | 4478 |
|
|
2021
Q4 | $317K | Hold |
325
| – | – | ﹤0.01% | 4500 |
|
|
2021
Q3 | $645K | Buy |
325
+8
| +3% | +$17.7K | ﹤0.01% | 4338 |
|
|
2021
Q2 | $968K | Buy |
317
+236
| +291% | +$1.07M | ﹤0.01% | 4155 |
|
|
2021
Q1 | $623K | Buy |
81
+73
| +913% | +$493K | ﹤0.01% | 4098 |
|
|
2020
Q4 | $32K | Buy |
+8
| New | +$24K | ﹤0.01% | 4193 |
|
|
2019
Q3 | – | Sell |
-2
| Closed | -$49K | – | 4162 |
|
|
2019
Q2 | $49K | Hold |
2
| – | – | ﹤0.01% | 4108 |
|
|
2019
Q1 | $74K | Hold |
2
| – | – | ﹤0.01% | 4033 |
|
|
2018
Q4 | $58K | Sell |
2
-4
| -67% | -$230K | ﹤0.01% | 4057 |
|
|
2018
Q3 | $558K | Hold |
6
| – | – | ﹤0.01% | 3830 |
|
|
2018
Q2 | $583K | Hold |
6
| – | – | ﹤0.01% | 3799 |
|
|
2018
Q1 | $920K | Buy |
6
+1
| +20% | +$156K | ﹤0.01% | 3662 |
|
|
2017
Q4 | $788K | Hold |
5
| – | – | ﹤0.01% | 3662 |
|
|
2017
Q3 | $572K | Buy |
5
+1
| +25% | +$209K | ﹤0.01% | 3718 |
|
|
2017
Q2 | $2M | Hold |
4
| – | – | ﹤0.01% | 3378 |
|
|
2017
Q1 | $1.8M | Buy |
4
+1
| +33% | +$381K | ﹤0.01% | 3413 |
|
|
2016
Q4 | $854K | Hold |
3
| – | – | ﹤0.01% | 3605 |
|
|
2016
Q3 | $1.04M | Hold |
3
| – | – | ﹤0.01% | 3561 |
|
|
2016
Q2 | $984K | Buy |
3
+1
| +50% | +$530K | ﹤0.01% | 3611 |
|
|
2016
Q1 | $2.08M | Hold |
2
| – | – | ﹤0.01% | 3364 |
|
|
2015
Q4 | $2.86M | Hold |
2
| – | – | ﹤0.01% | 3248 |
|
|
2015
Q3 | $3.54M | Hold |
2
| – | – | ﹤0.01% | 3128 |
|
|
2015
Q2 | $5.45M | Hold |
2
| – | – | ﹤0.01% | 2978 |
|
|
2015
Q1 | $5.53M | Hold |
2
| – | – | ﹤0.01% | 2952 |
|
|
2014
Q4 | $7.7M | Hold |
2
| – | – | ﹤0.01% | 2662 |
|
|
2014
Q3 | $9.08M | Hold |
2
| – | – | ﹤0.01% | 2541 |
|
|
2014
Q2 | $11.1M | Hold |
2
| – | – | ﹤0.01% | 2464 |
|
|
2014
Q1 | $9.76M | Hold |
2
| – | – | ﹤0.01% | 2503 |
|
|
2013
Q4 | $6.05M | Hold |
2
| – | – | ﹤0.01% | 2690 |
|
|
2013
Q3 | $5.26M | Hold |
2
| – | – | ﹤0.01% | 2717 |
|
|
2013
Q2 | $3.09M | Buy |
+2
| New | +$3.06M | ﹤0.01% | 2909 |
|
Other funds holding PALI
PA
CC
OCA
RCM
EP
BCM
Vanguard Group's PALI Position: Q4 2025 in Review
Vanguard Group opened a new position in Palisade Bio (PALI) in Q4 2025: 2,115,622 shares worth $4.97M. The stake represents ﹤0.01% of the portfolio and ranks #3256 among its holdings. This is a return to the name: Vanguard Group previously reported a position in PALI as recently as Q1 2024.
Vanguard Group first reported a position in PALI in Q2 2013 and has held it in 38 quarters since. The position peaked at $11.1M in Q2 2014. 86 funds tracked by Wall St. Rank hold PALI as of Q4 2025.
- Vanguard Group held 2,115,622 shares of Palisade Bio worth $4.97M as of Q4 2025.
- Palisade Bio was a new Vanguard Group position in Q4 2025.
- Palisade Bio made up ﹤0.01% of Vanguard Group's portfolio in Q4 2025, its #3256 holding.
- Vanguard Group first reported a position in Palisade Bio in Q2 2013 and has held it in 38 quarters since.
- Vanguard Group's Palisade Bio position peaked at $11.1M in Q2 2014.
- 86 funds tracked by Wall St. Rank held Palisade Bio as of Q4 2025.
Based on Vanguard Group's 13F filing for Q4 2025, filed 29 Jan 2026.